Targeting and Treating EGFR Exon 19 and 21 Alterations in Non-Small Cell Lung Cancer

Targeting and Treating EGFR Exon 19 and 21 Alterations in Non-Small Cell Lung Cancer

This activity will provide clinicians with the most up-to-date information on applying new care guidelines, understanding the associated trial data, and integrating these new therapies into their multidisciplinary care teams where TRAEs will be properly identified, managed, and mitigated to allow for optimal patient experiences and outcomes.

  • Provider:Medical Education Resources
  • Activity Link: https://mycme.com
  • Start Date: 2023-12-15 06:00:00
  • End Date: 2023-12-15 06:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
    Nursing: 1.0 hours
    Pharmacy: 1.0 hours
  • Commercial Support: Source: AstraZeneca (Any division) - Amount: 5000.0 - Is Kind Support: False
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner/Team Competence
  • Provider Ship: Jointly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.